Join Corbus Pharmaceuticals for an in-person and virtual investor event featuring key opinion leaders (KOLs) Ari Rosenberg, MD (UChicago Medicine), Glenn Hanna, MD (Dana-Farber Cancer Institute), and Cesar Augusto Perez Batista, MD (Sarah Cannon Research Institute), hosted by Yuval Cohen, Corbus CEO to discuss updated data from its Phase 1/2 clinical study of CRB-701 in over 75 participants with head and neck squamous cell carcinoma (HNSCC). Data will include clinical response durability as well as HNSCC patient subgroup analysis. These data will be presented as a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026, to be held May 29 – June 2, 2026 in Chicago, IL.

The ongoing three-part Phase 1/2 study has evaluated the safety, pharmacokinetics and efficacy of CRB-701 in over 317 participants with advanced solid tumors associated with high Nectin-4 expression. CRB-701 is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload.

Corbus recently announced broad alignment with the FDA on the registration path for CRB-701 in HNSCC.

A live question and answer session will follow the formal presentation and discussion.